This respected diagnostics company creates innovative, lab-accurate rapid diagnostic test results that are transforming community-based healthcare. The LumiraDx Platform is deployed by governments and leading healthcare institutions across laboratories, pharmacies and other workplaces, for screening, diagnosing and monitoring wellness and disease.
As a start-up, Lumira approached MBM when they launched their first diagnostic test for INR. They needed a supplier who could design and print packaging for diagnostic tests including instruments, test strips and kit cartons as well as print various items such as product inserts, user manuals and assorted labels.
MBM were able to offer Lumira DX a one-stop-shop for everything, and we easily accommodated additions to Lumira’s portfolio within their Point-of-Care platform.
When Covid hit, though, everything changed. While Lumira’s regular products became less of a priority, all efforts went in to providing rapid antigen (Ag) and antibody (Ab) testing kits. Volumes were huge, and we were providing tens of thousands of test strip labels, test strip packaging and all the ancillary printed items that went into the kits on a daily basis.
On top of this, each kit required a buffer solution which is used in the Covid testing process, and each of these buffer vials had to be batch controlled and labelled. Lumira shared this task with MBM, and a batch of 192,000 vials would initially take roughly two weeks to label by hand.
Grasping the opportunity to reduce the timescale for this task, MBM invested in a first vial labelling machine, quickly followed by a second. This game-changing move meant we could now label a batch of 192,000 vials in just 48 hours: in other words, two days instead of two weeks. This allowed Lumira DX to vastly increase its supply to the market throughout Europe.
Since the threat of Covid has reduced significantly over the past couple of years, Lumira DX have now returned to developing all the various ‘markers’ their Point-of-Care platform can diagnose, and they now have CE Marks for 12 different tests, with many more in the pipeline. MBM continue to provide all the print, packaging and labels for all of these different tests.
MBM are now a key partner to Lumira DX and, in July 2024, it was announced that one of the world’s largest biotech companies, Roche Diagnostics, had acquired the Lumira business. The innovative solution we developed with Lumira will allow Roche to further expand its offering in decentralised patient care, driving global access to timely and actionable diagnostic results. MBM are currently poised to rebrand all Lumira’s print and packaging to Roche Diagnostics’ brand identity.
